HOUSE, PA — Third Arc Bio Inc. has administered the first dose of ARC101 to a patient in its inaugural first-in-human clinical trial. This milestone marks the company’s transition to ...

中国国家药监局药品审评中心(CDE)官网近日公示，百济神州(06160)的1类新药注射用BGB-B455临床试验申请获得受理。公开资料显示，这是一款CLDN6 ×CD3双 ...

ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement -- First-in-human study will evaluate the safety, tolerability, ...

Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have been given a consensus recommendation of “Buy” by ...

公开资料显示，bgb-b455是一种双特异性抗体(bsabs)，其靶向肿瘤细胞上的cldn6和t细胞上的cd3受体。 它可能以更耐受的方式提供CLDN6依赖性抗肿瘤免疫 ...

Context Therapeutics Inc.’s CNTX share price has surged by 13.22%, which has investors questioning if this is right time to ...

Context Therapeutics Inc.’s CNTX share price has dipped by 11.07%, which has investors questioning if this is right time to buy.

HC Wainwright reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX – Free Report) in a report released ...

Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting claudin 6 (CLDN6)-positive ...

a critical step in assessing its potential as a novel T cell-engaging bispecific antibody for CLDN6-positive ovarian, endometrial, and testicular cancers.” “We ended the year with cash and ...

CTIM-76 first patient dosed in January 2025Cash and cash equivalents of $94.4 million as of December 31, 2024Company expects its cash and cash ...

Image Credit: Sino Biological Inc. Loaded anti-GPRC5D antibody on Protein A Biosensor binds Human GPRC5D-Detergent Protein (His & FLAG Tag) with an affinity constant of 58.1 nM as determined in ...